Tilray Advances Global Medical Cannabis Strategy With New Acquisition Deal

Cannabis giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) continues diversifying its business into a wellness powerhouse and consumer packaged goods company, with a new acquisition announced on Monday.

What Happened

The acquisition agreement includes the purchase of HelloMD Corporation, a digital healthcare and patient engagement platform, the company said in a press release. The companies didn’t disclose the financial terms of the deal.

Why It Matters

The transaction is expected to strengthen Tilray’s ability to connect directly with patients through telehealth, education, physician consultations, and ongoing support.

Furthermore, the acquisition will create a fully integrated medical cannabis platform in Canada and support Tilray’s broader global growth strategy by improving patient access, engagement, and clinical services.

HelloMD supports patients through telehealth consultations, educational resources, and personalized medical cannabis guidance.

The acquisition adds to Tilray’s existing healthcare infrastructure, which spans EU-GMP certified cultivation and manufacturing, pharmaceutical distribution through CC Pharma, medical cannabis clinics, digital pharmacy services, and patient access platforms across North America, Europe, Australia and other international markets.

According to Blair MacNeil, President of Tilray Canada, this business combination creates a “more connected pathway for patients and healthcare practitioners in Canada.”

“This acquisition establishes a fully vertically integrated medical cannabis framework for Tilray in Canada while strengthening our broader global platform, expanding patient engagement, practitioner support, and access in regulated medical markets,” MacNeil continued.

TLRY Price Action

Tilray’s shares traded 0.22% lower at $4.4801 per share at the time of writing on Wednesday.